Evaluation of ProspectiveHLA-B*13:01Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy | Zendy

Hong Liu | Zendy; Zhenzhen Wang | Zendy; Fangfang Bao | Zendy; Chuan Wang | Zendy; Lele Sun | Zendy; Huimin Zhang | Zendy; Gongqi Yu | Zendy; Zihao Mi | Zendy; Jianke Li | Zendy; Lulu Li | Zendy; Qing Zhao | Zendy; Zhenhua Yue | Zendy; Wei Zhao | Zendy; Wenjun Yu | Zendy; Jing Cao | Zendy; Fei Xiong | Zendy; Yaru Wang | Zendy; Zemin Chai | Zendy; Xiujun Cheng | Zendy; Yuan Zhang | Zendy; Fanghui Fu | Zendy; Xiaoqiao Lang | Zendy; Xiaoling Wang | Zendy; Astrid Irwanto | Zendy; Hana Krismawati | Zendy; Xi’an Fu | Zendy; Yonghu Sun | Zendy; Jiabao You | Zendy; Jian Liu | Zendy; Qing Pan | Zendy; Tongsheng Chu | Zendy; Dianchang Liu | Zendy; Shumin Chen | Zendy; Jianping Shen | Zendy; Liangbin Yan | Zendy; Guocheng Zhang | Zendy; Jianjun Liu | Zendy; Furen Zhang | Zendy; Li Xiong | Zendy; Jun Yang | Zendy; Jinlan Li | Zendy; Wei Ke | Zendy; Ming Li | Zendy; Yong Ning | Zendy; Xiong Jun-hao | Zendy; Mingzhou Xiong | Zendy; Bin Yang | Zendy; Qizhi Duan | Zendy; Hong Wang | Zendy; Wei Li | Zendy; Yanfei Kuang | Zendy; Junhua Li | Zendy; Lamei Wang | Zendy; Qiuyang Cao | Zendy; Peng Xiao | Zendy; Bangzhong Xiao | Zendy; Lianhua Zhang | Zendy; Zhao-Xing Lin | Zendy; Yaofei Wang | Zendy; Yun-Liang Shen | Zendy; Liying Yan | Zendy; Wenbin Wu | Zendy; Zheng Hu | Zendy; Xianfa Zhan | Zendy; Wanghua Li | Zendy; Xiujian Shang | Zendy; Yujun Xu | Zendy; Qiao Liu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of ProspectiveHLA-B*13:01Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy

Author(s) -

Hong Liu,

Zhenzhen Wang,

Fangfang Bao,

Chuan Wang,

Lele Sun,

Huimin Zhang,

Gongqi Yu,

Zihao Mi,

Jianke Li,

Lulu Li,

Qing Zhao,

Zhenhua Yue,

Wei Zhao,

Wenjun Yu,

Jing Cao,

Fei Xiong,

Yaru Wang,

Zemin Chai,

Xiujun Cheng,

Yuan Zhang,

Fanghui Fu,

Xiaoqiao Lang,

Xiaoling Wang,

Astrid Irwanto,

Hana Krismawati,

Xi’an Fu,

Yonghu Sun,

Jiabao You,

Jian Liu,

Qing Pan,

Tongsheng Chu,

Dianchang Liu,

Shumin Chen,

Jianping Shen,

Liangbin Yan,

Guocheng Zhang,

Jianjun Liu,

Furen Zhang,

Li Xiong,

Jun Yang,

Jinlan Li,

Wei Ke,

Ming Li,

Yong Ning,

Xiong Jun-hao,

Mingzhou Xiong,

Bin Yang,

Qizhi Duan,

Hong Wang,

Wei Li,

Yanfei Kuang,

Junhua Li,

Lamei Wang,

Qiuyang Cao,

Peng Xiao,

Bangzhong Xiao,

Lianhua Zhang,

Zhao-Xing Lin,

Yaofei Wang,

Yun-Liang Shen,

Liying Yan,

Wenbin Wu,

Zheng Hu,

Xianfa Zhan,

Wanghua Li,

Xiujian Shang,

Yujun Xu,

Qiao Liu

Publication year - 2019

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2018.5360

Subject(s) - dapsone , medicine , leprosy , prospective cohort study , incidence (geometry) , adverse effect , rifampicin , surgery , dermatology , tuberculosis , pathology , physics , optics

Dapsone hypersensitivity syndrome (DHS) is the most serious adverse reaction associated with dapsone administration and one of the major causes of death in patients with leprosy, whose standard treatment includes multidrug therapy (MDT) with dapsone, rifampicin, and clofazimine. Although the HLA-B*13:01 polymorphism has been identified as the genetic determinant of DHS in the Chinese population, no studies to date have been done to evaluate whether prospective HLA-B*13:01 screening could prevent DHS by identifying patients who should not receive dapsone.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research